Novavax NVAX Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $440.3M+335% | -$187.5M+65.6% | -$545.06M+17.2% | -$657.94M+62.3% | ||
| $27.61M-43.1% | $48.5M+17.6% | $41.23M+41.9% | $29.05M+129% | ||
| $36.02M-25.2% | $48.15M-43.6% | $85.36M-34.5% | $130.3M-29.0% | ||
| $98.19M+5,783% | $1.67M— | $0— | —— | ||
| —— | —— | —— | $477.8M+5,285% | ||
| -$322.57M+21.1% | -$408.95M— | —— | $1B+66.9% | ||
| —— | —— | —— | -$249.17M-236% | ||
| —— | $23.57M— | —— | —— | ||
| -$622.94M— | —— | —— | -$1.05B-179% | ||
| —— | -$87.26M+87.8% | -$713.97M-71.7% | -$415.94M— | ||
| $5.69M-56.4% | $13.06M-75.7% | $53.77M-39.6% | $89.06M+54.9% | ||
| —— | —— | —— | —— | ||
| $353.74M-20.2% | $443.55M— | —— | $0— | ||
| —— | —— | -$58.81M+36.8% | -$92.99M— | ||
| —— | —— | $0-100% | $175.25M— | ||
| $10.07M+152% | $3.99M-86.3% | $29.1M-70.5% | $98.52M-23.0% | ||
| —— | —— | —— | $355.96M— | ||
| —— | -$7.8M-338% | $3.27M-27.6% | $4.52M— | ||
| -$303.62M-688% | -$38.52M— | —— | —— | ||
| $15.05M-14.4% | $17.57M+1.3% | $17.35M-3.8% | $18.04M-7.2% | ||
| $8.81M+828% | $949K+399% | $190K-98.9% | $17.98M+42.6% | ||
| $0-100% | $51.95M— | $0— | $0— | ||
| —— | $4.13M-59.0% | $10.08M— | —— | ||
| -$622.94M— | —— | —— | -$1.05B-179% | ||
| —— | —— | —— | -$249.17M-236% | ||
| —— | $23.57M— | —— | —— | ||
| $1.95M-90.7% | $20.97M-71.0% | $72.2M-83.9% | $447.6M— | ||
| $5.69M-56.4% | $13.06M-75.7% | $53.77M-39.6% | $89.06M+63.4% | ||
| $353.74M-20.2% | $443.55M— | —— | $0— | ||
| $0-100% | $192.64M— | $0— | —— | ||
| —— | $0— | $0— | —— | ||
| $10.07M+152% | $3.99M-86.3% | $29.1M-70.5% | $98.52M-23.0% | ||
| —— | —— | —— | —— | ||
| -$4.8M-468% | $1.31M+721% | $159K— | —— | ||
| $8.81M+828% | $949K+399% | $190K-98.9% | $17.98M— | ||
| —— | -$100.32M+86.9% | -$767.74M-52.0% | -$504.99M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Novavax generate?
- Novavax (NVAX) generated -$384.9M in operating cash flow over the trailing twelve months.
- What is Novavax's free cash flow?
- After $5.4M of capital expenditures, Novavax's free cash flow was -$389.7M over the trailing twelve months, down 288.4% year over year.
- Where does Novavax's cash flow data come from?
- Every line is extracted from Novavax's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
